Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab
Italo Francesco Aromolo, Carlo Alberto Maronese, Chiara Moltrasio, Francesca Boggio, Silvia Alberti Violetti, Gianluca Avallone, Nicole Morini, Carlo Giovanni Carrera, Giovanni Genovese, Angelo Valerio Marzano
Abstract
We describe a patient with psoriasis who developed pyoderma gangrenosum while on treatment with brodalumab, an anti-interleukin (IL)-17 receptor monoclonal antibody. Genetic analyses revealed heterozygous polymorphisms within the promoter region of the IL-6 (promoter polymorphism –174 G/C) and IL-10 genes (promoter polymorphism –1082 A/G).
Topics & Concepts
Pyoderma gangrenosumPsoriasisMedicineMonoclonalPromoterImmunologyDermatologyMonoclonal antibodyGeneGeneticsAntibodyBiologyInternal medicineGene expressionDiseaseAutoimmune and Inflammatory DisordersPsoriasis: Treatment and PathogenesisHidradenitis Suppurativa and Treatments